25
Apr
2024
Day One’s Home Run, Big Pharma’s Missed Opportunity, and Tessier-Lavigne Rides Again
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Apr
2024
WuXi Feels Heat, Cerevel Hits Parkinson’s Goal & More GLP-1 Good News
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Apr
2024
Metsera Secures $290M to Follow Fast in Obesity Drug R&D
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Apr
2024
New Tools & Techniques for Biology: David Liu on The Long Run
Today’s guest on The Long Run is David Liu. David is a professor of chemistry and chemical biology at Harvard University, and a core institute member at the Broad Institute of Harvard and MIT. In biotech industry world, he’s a founder or co-founder of a long list of companies, including Beam Therapeutics, Prime Medicine, Editas Medicine, Chroma Medicine, and Exo... Read More
11
Apr
2024
Vertex Antes for Alpine, Regeneron Faces DOJ Scrutiny, & the Illumina Shakeup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Apr
2024
Meet the Timmerman Traverse for Sickle Forward Team
I’m thrilled to announce a new initiative to raise $1 million to fight sickle cell disease. It’s the Timmerman Traverse for Sickle Forward. A team of 21 biotech leaders are banding together for Sickle Forward in 2024. It’s a nonprofit dedicated to improving newborn screening and treatment of sickle cell disease in Africa. When we hit that goal, we will... Read More
8
Apr
2024
Meet the Timmerman Traverse for Life Science Cares 2024 Team
The Timmerman Traverse for Life Science Cares is back for a $1 million mission to fight poverty in 2024. This year’s team is coming together in common cause. We will bond together on a pair of spectacular hikes in the Pacific Northwest. We will cover 20 miles of trails, with more than 7,000 feet of elevation gain, over two days... Read More
4
Apr
2024
A ProfoundBio Windfall, Amylyx Yanks Failed ALS Drug, & Verve’s Rough Patch
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Mar
2024
Boundless’ IPO, Merck’s Acceleron Win, & Moderna’s $750M Flu Vaccine Boost
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Mar
2024
Megarounds Return, AZ Buys a Radiopharma Player, & Lonza’s California Dream
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Mar
2024
Clasp, Backed by Catalio, Third Rock & Novo, Gets $150M for Specific T-cell Engagers
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Mar
2024
Madrigal’s Historic First for MASH, IFM’s Hat Trick, & BIO on Election Defense
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Mar
2024
Startups Challenge Vertex, BMS, Takeda & the Weight Loss Drug Revival Continues
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Mar
2024
Early Detection, and Treatment, for Alzheimer’s: Valerie Daggett on The Long Run
Today’s guest on The Long Run is Valerie Daggett. Valerie is the founder and CEO of Seattle-based AltPep. This company is working on an unusual diagnostic-and-therapeutic strategy against Alzheimer’s disease. I wrote about the company in June 2023 when it raised $53 million in a Series B financing that included Section32, Alexandria Real Estate Equities, and Eli Lilly among others.... Read More
21
Feb
2024
Joy, Gratitude and Next Steps for Timmerman Traverse
Reporting this morning from Tanzania. I’m feeling joyful and grateful. My latest biotech team wrapped up another $1 million Timmerman Traverse fundraising campaign for the Damon Runyon Cancer Research Foundation. All 20 members of the team reached the summit of Kilimanjaro, the highest peak in Africa at 19,341 feet. We raised awareness of Damon Runyon’s national network of brilliant, brave... Read More
20
Feb
2024
Timmerman Traverse for Damon Runyon, Kilimanjaro 2024 Photo Gallery
The Timmerman Traverse for Damon Runyon Cancer Research Foundation is in the books. We have raised about $1.1 million for this national network of brilliant, brave and bold young scientists. All 20 members of the team made it to the summit of Kilimanjaro, the highest peak in Africa, at 19,341 feet. It’s an experience none of us will ever forget. ... Read More
9
Feb
2024
CRISPR to Protect the Bone Marrow & Attack Cancer: Robert Ang on The Long Run
Today’s guest on The Long Run is Robert Ang. Robert is the CEO of Cambridge, Mass.-based Vor Bio. The company is working on what I think you could call an elegant application of CRISPR gene editing for the treatment of acute myeloid leukemia. The idea here takes some explaining but is pretty simple. Patients with acute myeloid leukemia typically get... Read More
7
Feb
2024
Scion Starts with $310M to Build ‘Exceptional’ Biotech Startups
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Feb
2024
Vertex’s Next Big Thing, Regeneron’s Cell Therapy Play, & Takeda Bets on Protagonist
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Jan
2024
Sanofi Shells Out for Inhibrx, CG’s Breakout IPO, & a Cure for a Rare Deafness
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.